LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 29, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in April:
- EASL International Liver Congress in Vienna, Austria
° Valerie Sier-Ferreira, Ph.D., principal scientist of immunology research at uniQure, will present “Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression” on Thursday, April 11 at 10:00 a.m. CET.
° Anna Majowicz, Ph.D., scientist at uniQure, will present “Adeno-associated virus-serotype-specific transduction patterns in mice and non-human primates liver tissue: Implications for therapeutic efficacy” on April 11 at the 10:00 a.m. CET poster session.
- American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting in Washington, D.C.
° uniQure will deliver multiple data presentations at the meeting, which takes place Monday, April 29 through Thursday, May 2. Specific details to follow when the meeting abstracts are released.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. www.uniQure.com
uniQure Contacts
| For Investors: | | For Media: |
| | | |
| Maria E. Cantor | Eva M. Mulder | Tom Malone |
| Direct: 339-970-7536 | Direct: +31 20 240 6103 | Direct: 339-970-7558 |